.png){kind=icon}
.png){kind=icon}
Return
Mapping the Multifaceted Roles of ZNF280A: Insights into Prognosis, Immunity, and Function Across Pan-Cancer
.png){kind=icon}
PRE
AI
DOI：10.2174/0109298673359029250316111019.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Introduction ZNF280A, a pivotal member of the zinc finger protein family, is significantly involved in vital cellular functions including cell proliferation, programmed cell death, cellular invasion, metastasis, and resistance to therapeutic drugs across various malignancies. However, its comprehensive role in pan-cancer has not been thoroughly investigated.Methods This research aims to elucidate the oncogenic and immunological functions of ZNF280A across different types of cancer. We conducted an extensive analysis of ZNF280A expression levels, prognostic significance, functional pathways, methylation status, and interactions with immune cells, while also examining immune infiltration patterns and responses to immunotherapy using diverse databases.Results Our findings reveal that ZNF280A expression is significantly upregulated in numerous cancers, correlating with adverse patient prognosis. This association appears to be linked to its involvement in key cancer-related pathways, including the Ras signaling pathway, and its correlation with ZNF280A methylation levels, microsatellite instability (MSI), tumor mutational burden (TMB), and the dynamics of immune cells. Notably, ZNF280A seems to undermine anti-tumor immunity and the effectiveness of immunotherapeutic approaches by promoting the infiltration of immune cells and compromising the functionality of cytotoxic T lymphocytes.Conclusion These findings suggest that ZNF280A holds promise as a valuable indicator for forecasting patient outcomes and assessing the effectiveness of immunotherapy, thereby opening avenues for further exploration into targeted therapeutic approaches.
Keywords:
ZNF280A
pan-cancer
immune infiltration
prognostic biomarker
immunotherapy response
T lymphocytes
Journal
IF:
3.5
Papers:
7.0K
Citations:
2.1W
Organization
No organization information available
Cited Papers